Table 1 General inputs used in the model
Input | value | comment | source |
|---|---|---|---|
Patient characteristics | patients from Latin-American Countries randomised in the PARADIGM-HF | 3 | |
Mean age (years) | 63 | 3 | |
Female % | 27.30% | 3 | |
NYHA I % | 7.5% | 3 | |
NYHA II % | 81.6% | 3 | |
NYHA III % | 10.9% | 3 | |
NYHA IV % | 0.0% | 3 | |
LVEF % | 28.3 | 3 | |
Ischaemic aetiology % | 43.1% | 3 | |
Previously hospitalised for HF % | 53.9% | 3 | |
Mean SBP (mmHg) | 118.6 | 3 | |
Mean heart rate (bpm) | 70.6 | 3 | |
Mean eGFR (mL/min/1.73m2) | 68.7 | 3 | |
Prior ACEi use | 67.1% | 3 | |
Prior ARB use | 33.3% | 3 | |
Beta blocker use | 92.3% | 3 | |
Mineralocorticoid receptor antagonist use | 64.5% | 3 | |
Health states probabilities | |||
Hospitalization for HF | 2.69% | modelled monthly probability | 3 |
Cardiovascular Mortality | 0.58% | modelled monthly probability | 3 |
Utilities | |||
reduction for each year with HF | -0.008 | 3, 19 | |
basal utility in HF | 0.807 | 3, 19 | |
Discount rate | |||
Outcomes | 5% | discount rate usually applied in HE studies in Argentina | |
Costs | 31.64% | according to the BADLAR rate, a return of investment rate considering the opportunity cost of capital | 10 |
Cost-Effectiveness Threshold | ≤ 1 GDP per capita | as suggested by the National Commission for Health Technology Assessment | 27 |
Time Horizon | 30 -years | 19 | |